Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- WORLD NEWS IN BRIEF
May 17, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 17, 2004
- Terumo Aims for 10th Consecutive Year of Growth in FY2004
May 3, 2004
- MEDICAL DEVICE NEWS IN BRIEF
May 3, 2004
- DIAGNOSTIC NEWS IN BRIEF
May 3, 2004
- WORLD NEWS IN BRIEF
May 3, 2004
- Meet the Leaders (32)
May 3, 2004
- AstraZeneca Committed to Maintaining Top Position in Oncology
May 3, 2004
- Tokushukai Group to Establish Large-scale Clinical Trial Network
May 3, 2004
- Sankyo Aims for \15 Bil. Sales in China by 2010
May 3, 2004
- JOS Prepares Photodynamic Therapy GL
May 3, 2004
- FPMAJ Petitions for 8-Year Data Protection Period for New Drugs
May 3, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 3, 2004
- BUSINESS NEWS IN BRIEF
May 3, 2004
- Results of Study on Combination of PTX, CBDCA Reported
May 3, 2004
- BUSINESS NEWS IN BRIEF
May 3, 2004
- Zyrtec Significantly Reduces Symptoms of Pollinosis
May 3, 2004
- WEBSITE NEWS
May 3, 2004
- Technomics Analyzes Drugs Discontinued in Development 1985-2003
May 3, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
May 3, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…